Study validates clinical utility of pan-tumor predictive biomarker for checkpoint inhibitor immunotherapy benefit
by Strata OncologyDevelopment of an integrative immunotherapy response score (IRS) model to stratify PD-(L)1 therapy benefit in patients with advanced solid tumors.aReal-world treatment an
Updated on: February 03,2024
Study validates clinical utility of pan-tumor predictive biomarker for checkpoint inhibitor immunotherapy benefit
by Strata OncologyDevelopment of an integrative immunotherapy response score (IRS) model to stratify PD-(L)1 therapy benefit in patients with advanced solid tumors.aReal-world treatment an
Updated on:February 03,2024
